Table 2.
Sample Name | CASRN | Structure | SBE Antagonist | WNT Antagonist | RAR Antagonist | SHH Antagonist | ||||
---|---|---|---|---|---|---|---|---|---|---|
IC50 (μM) | Efficacy (%) | IC50 (μM) | Efficacy (%) | IC50 (μM) | Efficacy (%) | IC50 (μM) | Efficacy (%) | |||
Ferbam | 14484-64-1 | 0.05 | −80.99 | 0.57 | −66.42 | 0.83 | −93.29 | 0.05 | −87.88 | |
Ziram | 137-30-4 | 0.52 | −93.60 | 0.85 | −81.79 | 1.39 | −106.31 | 0.42 | −92.50 | |
Sodium dimethyldithiocarbamate | 128-04-1 | 9.14 | −68.19 | Inactive | Inactive | 17.37 | −93.31 | 6.73 | −87.30 |
Potency (IC50) and efficacy (activity %) in inhibiting TGFβ WNT, RAR, and SHH pathways by ferbam, ziram, and sodium dimethyldithiocarbamates were compared in the table.